UCB Reports FINTEPLA Study Showing Sustained LGS Benefits
Atlanta, Georgia, August 5, 2026 UCB has announced the publication of a post hoc analysis in Epilepsia Open demonstrating...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Atlanta, Georgia, August 5, 2026 UCB has announced the publication of a post hoc analysis in Epilepsia Open demonstrating...
Bagsværd, Denmark, August 5, 2026 Novo Nordisk has secured a significant legal victory after the District Court of The...
BOCA RATON, Fla., June 19, 2026 5W AI Communications has released its Pharma / Rx AI Visibility Index 2026,...
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
